Lucas Restrepo, MD
Neurology · Los Angeles, CANPI 1750325163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,608 of the $133,135 with a category attached, or 71.8%. Eisai Inc. accounts for 61.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $77,869, more than ten times the $148 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $842.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$82K
- Lilly USA, LLC$37K
- Biogen$10K
- Ipsen Biopharmaceuticals, Inc$4K
- MDD US Operations, LLC$298
- AstraZeneca$121
- plus $44 from 2 others
Across 39 payments — averaging $2447.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$95K
What the payments were for
- Consulting fees$19,00814%
- Speaking & faculty fees$95,60872%
- Travel & lodging$14,78511%
- Food & beverage$3,7343%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 117 | $81,743 |
| Lilly USA, LLC | 29 | $36,934 |
| Biogen | 5 | $10,217 |
| Ipsen Biopharmaceuticals, Inc | 2 | $3,778 |
| MDD US Operations, LLC | 1 | $298 |
| AstraZeneca | 1 | $121 |
| AbbVie | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,135 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 12 | $10,082 |
| Memantine Hcl ErMemantine Hcl | 19 | $4,873 |
| Memantine Hcl | 51 | $1,849 |
| Baclofen | 22 | $1,411 |
| Donepezil Hcl | 89 | $1,371 |
| Sumatriptan Succinate | 12 | $904 |
| Duloxetine Hcl | 27 | $809 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $528 |
| Gabapentin | 25 | $452 |
| Lamotrigine | 14 | $450 |
| Amitriptyline Hcl | 11 | $343 |
| Tizanidine Hcl | 13 | $187 |
| Atorvastatin Calcium | 27 | $101 |
| ClopidogrelClopidogrel Bisulfate | 15 | $58 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.